Figure:
![Figure:. Extensive cGvHD Treatment effect estimated from Cox model adjusted for status of disease and source of stem cells Hazard ratio (ATG vs. Control)=0.20, 95%-CI [0.10,0.39], p<0.0001](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/116/21/10.1182_blood.v116.21.212.212/3/bld0011000210004.jpeg?Expires=1746835112&Signature=Vf9k1m5QWiByWZh6ds0k25xIDh8rlgYWRBXFwlrXFI4KUOLROsTYHWoGdKQmz-HBcNgcWHvNG9xGGGBNPNPHQHT5QrxZ~AcujfwJ~324UM0BniVORvNo~dCKc9HNVTsvI6NhPxneO3~TKjOyxuOyUxssyYMOplp~Di9jW~qhAaHGBTFsQNBj0TeJ7PBnlX-Y8JY3mCmc~X4F3AdymmYZtwDEQS~tylSgFy4dgY-GO6KA24d3AA~ae50DxPPyr44uw~YJlOYmjrgbC2-AQ4ltm-iWtMYIGUKMro94kpHMl8Tlsw-bXo5iMXtZoZubNmSnuEqzVIXBtFYFfPsMdfw6yQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Extensive cGvHD Treatment effect estimated from Cox model adjusted for status of disease and source of stem cells Hazard ratio (ATG vs. Control)=0.20, 95%-CI [0.10,0.39], p<0.0001
Extensive cGvHD Treatment effect estimated from Cox model adjusted for status of disease and source of stem cells Hazard ratio (ATG vs. Control)=0.20, 95%-CI [0.10,0.39], p<0.0001
